Drug intelligence / Profile preview

rCSP

Development stage: Phase 1
Lead developer: Center for Vaccine Development and Global Health
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

rCSP is a recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine. It is designed to induce an immune response, specifically anti-CSP antibodies, against the circumsporozoite protein of the Plasmodium falciparum parasite, which is a key target for malaria vaccines. It has been investigated in Phase 1 clinical trials for the prevention of Plasmodium falciparum infection (malaria), often administered with an adjuvant such as GLA-LSQ.

Other names: recombinant circumsporozoite proteinrecombinant circumsporozoite protein antigenfull-length Plasmodium falciparum circumsporozoite protein-based vaccine

Targets

CSP (Circumsporozoite protein)

Beyond the preview

Go deeper on rCSP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rCSP.

Explore the full profile